A research team of the CNIO and the HKUST identifies how some gliomas develop chemoresistance
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) * Patients with glioma - a very common type of tumour originating in the brain - see improvement in survival rates with combined treatment of radiotherapy plus temozolomide* Researchers found a novel mechanism on how tumours evade chemotherapy through genomic rearrangements of the MGMT DNA repair gene* This finding is potentially relevant for updating the methods used to monitor temozolomide efficacy. Genomic rearrangement could be a marker to be detected in blood samples and help make therapeutic decisions (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 4, 2020 Category: Cancer & Oncology Source Type: news
NF decline but stable QOL in 1st year after temozolomide-based chemoradiotherapy
(NRG Oncology) A secondary analysis of the NRG Oncology clinical trial NRG-RTOG 0424, which initially reported a 73.1% 3-year overall survival rate, shows a decline in neurocognitive function (NCF) for half of the trial participants with high risk, low-grade gliomas (HR-LGGs) up to a year after receiving concurrent chemoradiotherapy with temozolomide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 25, 2019 Category: Cancer & Oncology Source Type: news
Can Patient-Derived Xenografts Predict Treatment Responses in Glioblastoma?
A new study has found that xenograft-based platform-independent gene signatures may help to predict patient response to chemotherapy, radiation, and combination therapy for glioblastoma. Investigators examined gene expression and treatment response data from 31 orthotopic glioblastoma patient-derived xenografts (PDXs), and developed gene signatures for radiotherapy, chemotherapy, and temozolomide response. Afterwards, the signatures were independently validated in a clinical cohort of glioblastoma patients. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
Class 4 medicine defect information: zoledronic acid 5mg solution for infusion
Ranbaxy (UK) Ltd a Sun Pharmaceutical Company, has informed the MHRA that some packs from a batch of zoledronic acid 5mg solution for infusion contain a patient information leaflet for temozolomide 18 (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - April 4, 2019 Category: Drugs & Pharmacology Source Type: news
Study in Advanced CRC Shows'Best of Precision Medicine'Study in Advanced CRC Shows'Best of Precision Medicine '
Dr Kerr discusses the ' preliminary results and interesting ' study of temozolomide and irinotecan in advanced refractory colorectal cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Novocure touts analysis of pivotal glioblastoma trial results
Novocure (NSDQ:NVCR) today touted the results of a retrospective sub-group analysis of its EF-14 Phase III pivotal trial in patients with newly diagnosed glioblastoma.
The analysis, which was published in the Journal of Neuro-Oncology, demonstrated that more time on Novocure’s Optune device predicted increased survival in people who received Optune plus temozolomide compared to those who received just temozolomide.
Gte the full story at our sister site, Drug Delivery Business News.
The post Novocure touts analysis of pivotal glioblastoma trial results appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 6, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news
Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System
In this article, we review the role of temozolomide in the management of patients with primary brain tumors, brain metastases, leptomeningeal carcinomatosis, and other selected CNS cancers. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2018 Category: Cancer & Oncology Authors: Karisa C. Schreck, MD, PhD, Stuart A. Grossman, MD Source Type: news
Combo Tx Boosts PFS in Advanced pNETs
(MedPage Today) -- Unprecedented 22-month median with temozolomide-capecitabine (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - October 7, 2018 Category: Endocrinology Source Type: news
MGMT promoter methylation associated with improved survival for patients with WHO Grade II Gliomas
(NRG Oncology) Further exploration into the endpoints of the NRGOncology/RTOG 0424 trial resulted in the discovery that MGMT promoter methylation is an independent prognostic biomarker of high-risk, low-grade glioma treated with temozolomide and radiation. This is the first study of its kind to validate the prognostic significance of MGMT promoter methylation in this patient population and treatment regimen. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 5, 2018 Category: Cancer & Oncology Source Type: news
Novocure touts quality-of-life analysis for glioblastoma patients treated with Optune-chemo combo
Novocure (NSDQ:NVCR) today touted an analysis published in JAMA Oncology showing that its Optune-temozolomide combination helped newly-diagnosed glioblastoma patients live longer without hurting their quality of life.
In a Phase III pivotal trial, researchers found that a higher proportion of patients treated with Optune and temozolomide reported stable or improved quality of life measures compared to those treated with just temozolomide.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure touts quality-of-life analysis for glioblastoma patients treated with Optune-chemo combo appeared ...
Source: Mass Device - February 1, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Pharmaceuticals Wall Street Beat NovoCure Source Type: news
